Tower Research Capital LLC (Trc) Biocryst Pharmaceuticals Inc Transaction History
Tower Research Capital LLC (Trc)
- $3.68 Billion
- Q3 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 12,500 shares of BCRX stock, worth $94,625. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,500
Previous 56,554
77.9%
Holding current value
$94,625
Previous $349,000
72.78%
% of portfolio
0.0%
Previous 0.01%
Shares
23 transactions
Others Institutions Holding BCRX
# of Institutions
278Shares Held
172MCall Options Held
625KPut Options Held
739K-
Vanguard Group Inc Valley Forge, PA20.3MShares$154 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$151 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$89.8 Million1.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$68.8 Million5.66% of portfolio
-
State Street Corp Boston, MA8.85MShares$67 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.41B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...